337 related articles for article (PubMed ID: 26857750)
1. Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress.
Zhang Z; Li B; Meng X; Yao S; Jin L; Yang J; Wang J; Zhang H; Zhang Z; Cai D; Zhang Y; Ning G
Sci Rep; 2016 Feb; 6():20848. PubMed ID: 26857750
[TBL] [Abstract][Full Text] [Related]
2. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
[TBL] [Abstract][Full Text] [Related]
3. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
Zhao L; Cang Z; Sun H; Nie X; Wang N; Lu Y
BMC Endocr Disord; 2017 Feb; 17(1):13. PubMed ID: 28241817
[TBL] [Abstract][Full Text] [Related]
4. Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity.
Guo T; Woo SL; Guo X; Li H; Zheng J; Botchlett R; Liu M; Pei Y; Xu H; Cai Y; Zeng T; Chen L; Li X; Li Q; Xiao X; Huo Y; Wu C
Sci Rep; 2016 Mar; 6():22612. PubMed ID: 26936230
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice.
Yamamoto T; Nakade Y; Yamauchi T; Kobayashi Y; Ishii N; Ohashi T; Ito K; Sato K; Fukuzawa Y; Yoneda M
World J Gastroenterol; 2016 Feb; 22(8):2512-23. PubMed ID: 26937139
[TBL] [Abstract][Full Text] [Related]
7. Berberine alleviates hepatic lipid accumulation by increasing ABCA1 through the protein kinase C δ pathway.
Liang H; Wang Y
Biochem Biophys Res Commun; 2018 Apr; 498(3):473-480. PubMed ID: 29505790
[TBL] [Abstract][Full Text] [Related]
8. Homocysteine Induces Hepatic Steatosis Involving ER Stress Response in High Methionine Diet-Fed Mice.
Ai Y; Sun Z; Peng C; Liu L; Xiao X; Li J
Nutrients; 2017 Apr; 9(4):. PubMed ID: 28368295
[TBL] [Abstract][Full Text] [Related]
9. Carboxylesterase 2 prevents liver steatosis by modulating lipolysis, endoplasmic reticulum stress, and lipogenesis and is regulated by hepatocyte nuclear factor 4 alpha in mice.
Li Y; Zalzala M; Jadhav K; Xu Y; Kasumov T; Yin L; Zhang Y
Hepatology; 2016 Jun; 63(6):1860-74. PubMed ID: 26806650
[TBL] [Abstract][Full Text] [Related]
10. FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease.
Liu C; Zhou B; Meng M; Zhao W; Wang D; Yuan Y; Zheng Y; Qiu J; Li Y; Li G; Xiong X; Bian H; Zhang H; Wang H; Ma X; Hu C; Xu L; Lu Y
J Hepatol; 2021 Jul; 75(1):150-162. PubMed ID: 33548387
[TBL] [Abstract][Full Text] [Related]
11. A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis.
Parafati M; Kirby RJ; Khorasanizadeh S; Rastinejad F; Malany S
Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30254132
[TBL] [Abstract][Full Text] [Related]
12. Naltrexone changes the expression of lipid metabolism-related proteins in the endoplasmic reticulum stress induced hepatic steatosis in mice.
Moslehi A; Nabavizadeh F; Zekri A; Amiri F
Clin Exp Pharmacol Physiol; 2017 Feb; 44(2):207-212. PubMed ID: 27813192
[TBL] [Abstract][Full Text] [Related]
13. The marine compound and elongation factor 1A1 inhibitor, didemnin B, provides benefit in western diet-induced non-alcoholic fatty liver disease.
Wilson RB; Chen YJ; Sutherland BG; Sawyez CG; Zhang R; Woolnough T; Hetherington AM; Peters KM; Patel K; Kennelly JP; Leonard KA; Schuurman M; Jacobs RL; Wang R; Borradaile NM
Pharmacol Res; 2020 Nov; 161():105208. PubMed ID: 32977024
[TBL] [Abstract][Full Text] [Related]
14. Elevation of liver endoplasmic reticulum stress in a modified choline-deficient l-amino acid-defined diet-fed non-alcoholic steatohepatitis mouse model.
Muraki Y; Makita Y; Yamasaki M; Amano Y; Matsuo T
Biochem Biophys Res Commun; 2017 May; 486(3):632-638. PubMed ID: 28322783
[TBL] [Abstract][Full Text] [Related]
15. Berberine ameliorates fatty acid-induced oxidative stress in human hepatoma cells.
Sun Y; Yuan X; Zhang F; Han Y; Chang X; Xu X; Li Y; Gao X
Sci Rep; 2017 Sep; 7(1):11340. PubMed ID: 28900305
[TBL] [Abstract][Full Text] [Related]
16. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte specific deletion of c-Met leads to the development of severe non-alcoholic steatohepatitis in mice.
Kroy DC; Schumacher F; Ramadori P; Hatting M; Bergheim I; Gassler N; Boekschoten MV; Müller M; Streetz KL; Trautwein C
J Hepatol; 2014 Oct; 61(4):883-90. PubMed ID: 24845607
[TBL] [Abstract][Full Text] [Related]
18. Berberine-loaded solid lipid nanoparticles are concentrated in the liver and ameliorate hepatosteatosis in db/db mice.
Xue M; Zhang L; Yang MX; Zhang W; Li XM; Ou ZM; Li ZP; Liu SH; Li XJ; Yang SY
Int J Nanomedicine; 2015; 10():5049-57. PubMed ID: 26346310
[TBL] [Abstract][Full Text] [Related]
19. Berberine inhibits free fatty acid and LPS-induced inflammation via modulating ER stress response in macrophages and hepatocytes.
Wang Y; Zhou X; Zhao D; Wang X; Gurley EC; Liu R; Li X; Hylemon PB; Chen W; Zhou H
PLoS One; 2020; 15(5):e0232630. PubMed ID: 32357187
[TBL] [Abstract][Full Text] [Related]
20. Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity.
Yan F; Wang Q; Lu M; Chen W; Song Y; Jing F; Guan Y; Wang L; Lin Y; Bo T; Zhang J; Wang T; Xin W; Yu C; Guan Q; Zhou X; Gao L; Xu C; Zhao J
J Hepatol; 2014 Dec; 61(6):1358-64. PubMed ID: 25016220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
